Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: NR
Nonpeptide agent · Cofactor, nucleoside or nucleotide
Detailed molecular class: Non-peptide nucleoside precursor
Supplied sequence or chemical reference
PubChem CID: 439924
Molecular formula: C11H15N2O5+
IUPAC: 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide
Source: PC-NR
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Precursor in NAD metabolism.
Evidence and critical reading
Reported scientific and empirical uses
Mitochondrial research · Replacement and nutritional context
NAD+ precursor marketed orally and intravenously. It is neither NAD+ nor NMN.
Human evidence
Human biomarker studies show metabolic effects, not lifespan extension. Oral evidence cannot be transferred to IV products.
Preclinical evidence
Pathway plausibility does not establish clinical outcome benefit.
Critical reading and limitations
A crossover trial in twelve older men changed the metabolome without improving muscle mitochondrial bioenergetics.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD<sup>+</sup> Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures.
1 g · Total daily amount
- Frequency
- Daily
- Duration
- 21 days
- Route
- Oral
- Context
- 12 older men; muscle NAD metabolome, not longevity.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID31412242 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Product/route-specific safety; 2026 IV comparison is small and retrospective. Long-term combination data remain limited.
Oral data do not validate infusion; the IV pilot was retrospective and brief.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID31412242 · Randomized controlled trial
Older men.
Oral, 21 days, crossover.
Increased muscle NAD metabolome without improved mitochondrial bioenergetics.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 12
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
nicotinamide riboside · 123 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT04562831 · The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.Registry status: Active, not recruitingLast update posted: October 5, 2026Query verification: October 16, 2026
NCT03821623 · Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older AdultsRegistry status: Active, not recruitingLast update posted: October 2, 2026Query verification: October 16, 2026
NCT04040959 · Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKDRegistry status: Active, not recruitingLast update posted: October 2, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-NR
PubChem nicotinamide riboside (CID 439924)
October 16, 2026
- PMID31412242
Elhassan YS, Kluckova K, Fletcher RS, Schmidt MS, Garten A, Doig CL, Cartwright DM, Oakey L, Burley CV, Jenkinson N, Wilson M, Lucas SJE, Akerman I, Seabright A, Lai YC, Tennant DA, Nightingale P, Wallis GA, Manolopoulos KN, Brenner C, Philp A, Lavery GG.
October 16, 2026
- PMID41704678
Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, Pojednic R.
October 16, 2026